Amicus Therapeutics (FOLD) A Look at Technical Overview

2

Amicus Therapeutics (NASDAQ:FOLD) shares traded 0.41% up during most recent session to reach at the closing price of $9.76. The stock exchanged hands 3.59 Million shares versus average trading capacity of 2.52 Million shares, yielding a market cap of $1.39 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $12.92 within the next 52-weeks. The mean target projections are based on 6 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Amicus Therapeutics (NASDAQ:FOLD) high price target of $18 and with a conservative view have low price target of $10.

Baird “Upgrades” Amicus Therapeutics (NASDAQ:FOLD) in a research note issued to investors on 1/24/17 to Outperform with price target of $10.

Additionally on 5/18/16 Bank of America “Initiates Coverage on” Amicus Therapeutics (NASDAQ:FOLD) to Buy setting price target at $10 and on 4/14/16 Baird “Initiates Coverage on” the stock to Neutral. Furthermore on 3/30/16 Goldman Sachs “Initiates Coverage on” the stock to Neutral at $10.

On the other hand the company has Relative Strength Index (RSI 14) of 60.98 along with Average True Range (ATR 14) of 0.49, Consequently Amicus Therapeutics (NASDAQ:FOLD)’s weekly and monthly volatility is 5.13%, 5.35% respectively. The company’s beta value is at 1.78.

In terms of Buy, Sell or Hold recommendations, Amicus Therapeutics (NASDAQ:FOLD) has analysts’ mean recommendation of 1.5. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Amicus Therapeutics (NASDAQ:FOLD)’s minimum EPS for the current quarter is at $-0.41 and can go high up to $-0.31. The consensus mean EPS for the current quarter is at $-0.36 derived from a total of 6 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.4 earnings per share for the same quarter during last year.

Previously Amicus Therapeutics (NASDAQ:FOLD) reported $-0.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.36 by $-0.03. The company posted an earnings surprise of -8.3%.

Amicus Therapeutics (NASDAQ:FOLD)’s revenue estimates for the current quarter are $6.72 Million according to 6 number of analysts, for the current quarter the company has high revenue estimates of $7.63 Million in contradiction of low revenue estimates of $5.5 Million. For the current year the company’s revenue estimates are $31.61 Million compared to low analyst estimates of $21.2 Million and high estimates of $37 Million according to 6 number of analysts.

Currently Amicus Therapeutics (NASDAQ:FOLD)’s shares owned by insiders are 1%, whereas shares owned by institutional owners are 97.6%. However the six-month change in the insider ownership was recorded 3.48%, as well as three-month change in the institutional ownership was recorded 9.65%.

Amicus Therapeutics (NASDAQ:FOLD) 52-week high price stands at $10.50 and low price stands at $4.41, its price distance from 52-week high is -7.05% while its distance from 52-week low price is 121.32%. The stock hit its 52-week high on 06/26/17, and 52-week low on 12/22/16.

Amicus Therapeutics (NASDAQ:FOLD)’s trailing twelve month revenues are $9.1 Million, whereas its price to sales ratio for the same period is 153.13. Its book value per share for the most recent quarter is $2.18 while its price to book ratio for the same period is 4.48, as for as the company’s cash per share for the most recent quarter is $1.96, however its price to cash per share ratio for the same period is 4.98. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.